Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation

Background Endothelial cell (EC) dysfunction involves reduced nitric oxide (NO) bioavailability due to NO synthase uncoupling linked to increased oxidation and reduced cofactor availability. Loss of endothelial function and NO bioavailability are associated with inflammation, including leukocyte act...

Full description

Bibliographic Details
Published in:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Main Authors: Samuel C. R. Sherratt, Peter Libby, Hazem Dawoud, Deepak L. Bhatt, R. Preston Mason
Format: Article
Language:English
Published: Wiley 2024-07-01
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.034076
_version_ 1849569973458960384
author Samuel C. R. Sherratt
Peter Libby
Hazem Dawoud
Deepak L. Bhatt
R. Preston Mason
author_facet Samuel C. R. Sherratt
Peter Libby
Hazem Dawoud
Deepak L. Bhatt
R. Preston Mason
author_sort Samuel C. R. Sherratt
collection DOAJ
container_title Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
description Background Endothelial cell (EC) dysfunction involves reduced nitric oxide (NO) bioavailability due to NO synthase uncoupling linked to increased oxidation and reduced cofactor availability. Loss of endothelial function and NO bioavailability are associated with inflammation, including leukocyte activation. Eicosapentaenoic acid (EPA) administered as icosapent ethyl reduced cardiovascular events in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) in relation to on‐treatment EPA blood levels. The mechanisms of cardiovascular protection for EPA remain incompletely elucidated but likely involve direct effects on the endothelium. Methods and Results In this study, human ECs were treated with EPA and challenged with the cytokine IL‐6 (interleukin‐6). Proinflammatory responses in the ECs were confirmed by ELISA capture of sICAM‐1 (soluble intercellular adhesion molecule‐1) and TNF‐α (tumor necrosis factor‐α). Global protein expression was determined using liquid chromatography–mass spectrometry tandem mass tag. Release kinetics of NO and peroxynitrite were monitored using porphyrinic nanosensors. IL‐6 challenge induced proinflammatory responses from the ECs as evidenced by increased release of sICAM‐1 and TNF‐α, which correlated with a loss of NO bioavailability. ECs pretreated with EPA modulated expression of 327 proteins by >1‐fold (P<0.05), compared with IL‐6 alone. EPA augmented expression of proteins involved in NO production, including heme oxygenase‐1 and dimethylarginine dimethylaminohydrolase‐1, and 34 proteins annotated as associated with neutrophil degranulation. EPA reversed the endothelial NO synthase uncoupling induced by IL‐6 as evidenced by an increased [NO]/[peroxynitrite] release ratio (P<0.05). Conclusions These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.
format Article
id doaj-art-79df8e5fb2eb4e8db8625da68cb4e4ce
institution Directory of Open Access Journals
issn 2047-9980
language English
publishDate 2024-07-01
publisher Wiley
record_format Article
spelling doaj-art-79df8e5fb2eb4e8db8625da68cb4e4ce2025-08-20T02:31:33ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802024-07-01131410.1161/JAHA.123.034076Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During InflammationSamuel C. R. Sherratt0Peter Libby1Hazem Dawoud2Deepak L. Bhatt3R. Preston Mason4Department of Molecular, Cellular, and Biomedical Sciences University of New Hampshire Durham NH USADepartment of Medicine, Cardiovascular Division, Brigham and Women’s Hospital Harvard Medical School Boston MA USANanomedical Research Laboratory Ohio University Athens OH USAMount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai New York NY USAElucida Research Beverly MA USABackground Endothelial cell (EC) dysfunction involves reduced nitric oxide (NO) bioavailability due to NO synthase uncoupling linked to increased oxidation and reduced cofactor availability. Loss of endothelial function and NO bioavailability are associated with inflammation, including leukocyte activation. Eicosapentaenoic acid (EPA) administered as icosapent ethyl reduced cardiovascular events in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) in relation to on‐treatment EPA blood levels. The mechanisms of cardiovascular protection for EPA remain incompletely elucidated but likely involve direct effects on the endothelium. Methods and Results In this study, human ECs were treated with EPA and challenged with the cytokine IL‐6 (interleukin‐6). Proinflammatory responses in the ECs were confirmed by ELISA capture of sICAM‐1 (soluble intercellular adhesion molecule‐1) and TNF‐α (tumor necrosis factor‐α). Global protein expression was determined using liquid chromatography–mass spectrometry tandem mass tag. Release kinetics of NO and peroxynitrite were monitored using porphyrinic nanosensors. IL‐6 challenge induced proinflammatory responses from the ECs as evidenced by increased release of sICAM‐1 and TNF‐α, which correlated with a loss of NO bioavailability. ECs pretreated with EPA modulated expression of 327 proteins by >1‐fold (P<0.05), compared with IL‐6 alone. EPA augmented expression of proteins involved in NO production, including heme oxygenase‐1 and dimethylarginine dimethylaminohydrolase‐1, and 34 proteins annotated as associated with neutrophil degranulation. EPA reversed the endothelial NO synthase uncoupling induced by IL‐6 as evidenced by an increased [NO]/[peroxynitrite] release ratio (P<0.05). Conclusions These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.https://www.ahajournals.org/doi/10.1161/JAHA.123.034076eicosapentaenoic acidendothelial functionnitric oxideproteomics
spellingShingle Samuel C. R. Sherratt
Peter Libby
Hazem Dawoud
Deepak L. Bhatt
R. Preston Mason
Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
eicosapentaenoic acid
endothelial function
nitric oxide
proteomics
title Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
title_full Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
title_fullStr Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
title_full_unstemmed Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
title_short Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
title_sort eicosapentaenoic acid improves endothelial nitric oxide bioavailability via changes in protein expression during inflammation
topic eicosapentaenoic acid
endothelial function
nitric oxide
proteomics
url https://www.ahajournals.org/doi/10.1161/JAHA.123.034076
work_keys_str_mv AT samuelcrsherratt eicosapentaenoicacidimprovesendothelialnitricoxidebioavailabilityviachangesinproteinexpressionduringinflammation
AT peterlibby eicosapentaenoicacidimprovesendothelialnitricoxidebioavailabilityviachangesinproteinexpressionduringinflammation
AT hazemdawoud eicosapentaenoicacidimprovesendothelialnitricoxidebioavailabilityviachangesinproteinexpressionduringinflammation
AT deepaklbhatt eicosapentaenoicacidimprovesendothelialnitricoxidebioavailabilityviachangesinproteinexpressionduringinflammation
AT rprestonmason eicosapentaenoicacidimprovesendothelialnitricoxidebioavailabilityviachangesinproteinexpressionduringinflammation